UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

The epidermal growth factor receptor (EGRF) in lung cancer

Translational respiratory medicine, 2015-02, Vol.3 (1), p.1-1, Article 1

2015

Link zum Volltext

Verfügbarkeit prüfen

Association of androgen receptor signature and RB1 , PTEN , TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5069-5069

2021

Link zum Volltext

Verfügbarkeit prüfen

Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5598-5598

2018

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation

Journal of neuro-oncology, 2014-03, Vol.117 (1), p.77-84

2014

Link zum Volltext

Verfügbarkeit prüfen

Analysis of two consecutive series of unresectable high-grade glioma (HGG) patients (pts) treated with or without neoadjuvant chemotherapy before estandar radiochemotherapy (CRT) and adjuvant temozolamide (TMZ)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e12504-e12504

2012

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of ROS1 translocation, HER2, and BRAF mutations in a cohort of advanced Non-Small Cell Lung Cancer (NSCLC) patients (p) triple negative (TN)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e22139-e22139

2015

Link zum Volltext

Verfügbarkeit prüfen

Tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) patients (p) based on EGFR mutations (m) status in serum only

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e19088-e19088

2013

Link zum Volltext

Verfügbarkeit prüfen

A protocol with adjuvant chemotherapy (CT) and radiotherapy (RT) for endometrial cancer: Results

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e16549-e16549

2013

Link zum Volltext

Verfügbarkeit prüfen

Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient

Clinical lung cancer, 2015-03, Vol.16 (2), p.e1-e3

2015

Link zum Volltext

Verfügbarkeit prüfen

Estrogen receptor β and TMPRSS2-ERG expression association with clinical outcomes in metastatic hormone-sensitive prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5077-5077

2022

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms in genes OPRM1, β-arrestin 2, STAT6, and COMT and clinical outcome to opioid therapy

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.9129-9129

2012

Link zum Volltext

Verfügbarkeit prüfen

Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18143-e18143

2012

Link zum Volltext

Verfügbarkeit prüfen

Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7540-7540

2012

Link zum Volltext

Verfügbarkeit prüfen

MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18131-e18131

2012

Link zum Volltext

Verfügbarkeit prüfen

Metástasis auricular en carcinoma renal de células claras

Gaceta Mexicana de oncología, 2015-07, Vol.14 (4), p.222-224

2015

Link zum Volltext

Verfügbarkeit prüfen

1148 POSTER DAB2 Interactive Protein (DAB2IP) Methylation in Serum DNA of Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Mutations

European journal of cancer (1990), 2011, Vol.47, p.S138-S138

2011

Link zum Volltext

Verfügbarkeit prüfen

Protecting essential health services in low-income and middle-income countries and humanitarian settings while responding to the COVID-19 pandemic

BMJ global health, 2020-10, Vol.5 (10), p.e003675

2020

Link zum Volltext

Verfügbarkeit prüfen

NOX2 deficiency enhances priming and activation of the NLRP3 inflammasome

Journal of allergy and clinical immunology, 2023-10

2023

Link zum Volltext

Verfügbarkeit prüfen

Protection against Respiratory Syncytial Virus by a Recombinant Newcastle Disease Virus Vector

Journal of Virology, 2006-02, Vol.80 (3), p.1130-1139

2006

Link zum Volltext

Verfügbarkeit prüfen

Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients

Journal of allergy and clinical immunology, 2021-08, Vol.148 (2), p.523-532.e8

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(31)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(8)
Oncology
(6)
Patients
(4)
Male
(3)
Middle Aged
(3)
Adult
(2)
Aged
(2)
Allergy
(2)
Autoimmune Diseases
(2)
Biomarkers
(2)
Cancer Therapies
(2)
Care And Treatment
(2)
Chemotherapy
(2)
Docetaxel
(2)
Dosage And Administration
(2)
Female
(2)
Hematology, Oncology And Palliative Medicine
(2)
Immunologic Deficiency Syndromes - Genetics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel

The epidermal growth factor receptor (EGRF) in lung cancer

Association of androgen receptor signature and RB1 , PTEN , TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy

Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation

Analysis of two consecutive series of unresectable high-grade glioma (HGG) patients (pts) treated with or without neoadjuvant chemotherapy before estandar radiochemotherapy (CRT) and adjuvant temozolamide (TMZ)

Prevalence of ROS1 translocation, HER2, and BRAF mutations in a cohort of advanced Non-Small Cell Lung Cancer (NSCLC) patients (p) triple negative (TN)

Tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) patients (p) based on EGFR mutations (m) status in serum only

A protocol with adjuvant chemotherapy (CT) and radiotherapy (RT) for endometrial cancer: Results

Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC)

Development and validation of a gene expression signature based on RB1 , PTEN,and TP53 in patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient

Estrogen receptor β and TMPRSS2-ERG expression association with clinical outcomes in metastatic hormone-sensitive prostate cancer

Polymorphisms in genes OPRM1, β-arrestin 2, STAT6, and COMT and clinical outcome to opioid therapy

Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib

Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study

MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations

Metástasis auricular en carcinoma renal de células claras

1148 POSTER DAB2 Interactive Protein (DAB2IP) Methylation in Serum DNA of Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Mutations

Protecting essential health services in low-income and middle-income countries and humanitarian settings while responding to the COVID-19 pandemic

NOX2 deficiency enhances priming and activation of the NLRP3 inflammasome

Protection against Respiratory Syncytial Virus by a Recombinant Newcastle Disease Virus Vector

Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients

Suchergebnisse filtern